Drugs Made In America Acquisition II
DMIIR · NASDAQ
About DMIIR
- Employees
- 0
- Headquarters
- New York City, New York
- Listed
- Sep 25, 2025
- Sector
- N/A
- Industry
- N/A
DMIIR key statistics
- Market cap
- 649.42M
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 19.27K
- Volume
- 18.21K
- Open price
- $0.0603
- High today
- $0.07
- Low today
- $0.07
- 52 Week high
- $0.17
- 52 Week low
- $0.05
Drugs Made In America Acquisition II (DMIIR) at a glance
Drugs Made In America Acquisition II (DMIIR) last traded at $0.07, with a market cap of 649.42M and a price-to-earnings ratio of 0.00.
Volume so far is 18.21K shares, in line with the average of 19.27K shares a day.
Over the past year Drugs Made In America Acquisition II has ranged from $0.05 to $0.17, and now sits 17% of the way up that range.
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0002+0.00%
- RDARRaadr$0.0002−16.67%
- AXGSolowin Holdings$0.04−25.65%
- AEFIAmerican EcoFuels$0.0009+12.50%
- SHFSSHF Holdings$0.1158+23.19%
- DVLTDatavault AI$0.067−49.55%
- MASNMaison Luxe$0.0002+0.00%
- XXII22nd Century Group$0.1048+18.55%
- NBNDNetBrands$0.0007+0.00%
- NEXRNexera Technologies$0.5454+21.77%
- TIPSTianrong Internet Products & Services$0.0011+57.14%
- AITXArtificial Intelligence Technology Solutions$0.0008−20.00%
Newly listed
Companies that went public in the past six weeks
- LYCALycia Therapeutics$26.11−9.50%
- DAVIDAVION HEALTHCARE$3.00−26.29%
- TCXBTCGX Acquisition Corp. II$10.28+0.10%
- CTYCITY THERAPEUTICS$20.86+0.34%
- IAMIambic Therapeutics$14.00−2.85%
- AMROAmaero$6.04+12.48%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.23−0.49%
- TRXBTRex Bio$13.79−0.58%
- RTSNRetension Pharmaceuticals$13.52−5.06%
- PAXGUPine Tree Acquisition$10.00−0.20%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.20+1.36%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.